Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X

Autor: Qin, N, de Cubas AA, Garcia Martin, R, Richter, S, Peitzsch, M, Menschikowski, M, Lenders, Jw, Timmers, Hj, Mannelli, M, Opocher, Giuseppe, Economopoulou, M, Siegert, G, Chavakis, T, Pacak, K, Robledo, M, Eisenhofer, G.

Publikováno v: International journal of cancer. 135(9)

Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-producing chromaffin cell tumors with diverse phenotypic features reflecting mutations in numerous genes, including MYC-associated factor X (MAX). To explore whether phenotypic difference

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f54c5472cdcd786e5de71c6709526acd
https://pubmed.ncbi.nlm.nih.gov/24676840

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

Autor: Saeed Elojeimy, Henri J L M Timmers, Neeta Pandit-Taskar, Rodney J. Hicks, Anca M. Avram, Stefano Fanti, Aaron T. Scott, David Taïeb, Elif Hindié, Benjamin Guillet, Domenico Rubello, Karel Pacak, Pietro Ghedini, Irene Virgolini, Sona Balogova

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (10), pp.2112-2137. ⟨10.1007/s00259-019-04398-1⟩
European Journal of Nuclear Medicine and Molecular Imaging, 46, 10, pp. 2112-2137
European Journal of Nuclear Medicine and Molecular Imaging, 46, 2112-2137
European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (10), pp.2112-2137. ⟨10.1007/s00259-019-04398-1⟩
Eur J Nucl Med Mol Imaging

Purpose: Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably charact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee59708ca1fecba1b666d0e06cbd1a47
https://hal-amu.archives-ouvertes.fr/hal-02899034

Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.

Autor: Calsina B; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. bcalsina@cnio.es., Piñeiro-Yáñez E; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Martínez-Montes ÁM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Caleiras E; Histopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Fernández-Sanromán Á; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Monteagudo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Torres-Pérez R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Bioinformatics for Genomics and Proteomics, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain., Fustero-Torre C; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Pulgarín-Alfaro M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Gil E; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Letón R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Jiménez S; Monoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., García-Martín S; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Martin MC; Molecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Roldán-Romero JM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Lanillos J; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Mellid S; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Santos M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Díaz-Talavera A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Rubio Á; Genomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., González P; Histopathology Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Hernando B; Computational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Bechmann N; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Dona M; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Calatayud M; Department of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain., Guadalix S; Department of Endocrinology, 12 de Octubre University Hospital, Madrid, Spain., Álvarez-Escolá C; Department of Endocrinology, La Paz University Hospital, Madrid, Spain., Regojo RM; Department of Pathology, La Paz University Hospital, Madrid, Spain., Aller J; Department of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain., Del Olmo-Garcia MI; Department of Endocrinology and Nutrition, University Hospital La Fe, Valencia, Spain., López-Fernández A; Department of Medical Oncology, Vall d'Hebrón Hospital, Barcelona, Spain., Fliedner SMJ; Neuroendocrine Oncology and Metabolism, Medical Department I, Center of Brain, Behavior, and Metabolism, University Medical Center Schleswig-Holstein Lübeck, Lübeck, Germany., Rapizzi E; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Fassnacht M; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany., Beuschlein F; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.; Klinik für Endokrinologie Diabetologie und Klinische Ernährung, Universitätsspital Zürich (USZ) und Universität Zürich (UZH), Zürich, Switzerland., Quinkler M; Endocrinology in Charlottenburg Stuttgarter Platz 1, Berlin, Germany., Toledo RA; Gastrointestinal and Endocrine Tumors, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Institute of Health Carlos III (ISCIII), Madrid, Spain., Mannelli M; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Timmers HJ; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Eisenhofer G; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Rodríguez-Perales S; Molecular Cytogenetics and Genome Engineering Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Domínguez O; Genomics Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Macintyre G; Computational Oncology Group, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Currás-Freixes M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Department of Endocrinology, Clínica Universidad de Navarra, Madrid, Spain., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Cascón A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Leandro-García LJ; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Montero-Conde C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain., Roncador G; Monoclonal Antibodies Core Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., García-García JF; Department of Pathology, MD Anderson Cancer Center, Madrid, Spain., Pacak K; Section of Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA., Al-Shahrour F; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Robledo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. mrobledo@cnio.es.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III (ISCIII), Madrid, Spain. mrobledo@cnio.es.

Publikováno v: Nature communications [Nat Commun] 2023 Feb 28; Vol. 14 (1), pp. 1122. Date of Electronic Publication: 2023 Feb 28.

Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.

Autor: Wallace PW; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Conrad C; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Brückmann S; Institute of Pathology, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Pang Y; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA., Caleiras E; Histopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro, Madrid, Spain., Murakami M; Medizinische Klinik and Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany., Korpershoek E; Department of Pathology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands., Zhuang Z; Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA., Rapizzi E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Kroiss M; Department of Internal Medicine, Division of Endocrinology, University Hospital, University of Würzburg, Würzburg, Germany., Gudziol V; Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Plastische Operationen, Städtisches Klinikum Dresden, Akademisches Lehrkrankenhaus der Technischen Universität Dresden, Dresden, Germany.; Departments of Otorhinolaryngology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Timmers HJ; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Mannelli M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Pietzsch J; Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.; Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany., Beuschlein F; Medizinische Klinik and Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany.; Department for Endocrinology, Diabetology and Clinical Nutrition, UniversitätsSpital Zürich, Zurich, Switzerland., Pacak K; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA., Robledo M; Hereditary Endocrine Cancer Group, CNIO, Madrid, Spain and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Klink B; Institute for Clinical Genetics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Department of Genetics, Laboratoire National de Santé, Dudelange, Luxembourg., Peitzsch M; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Gill AJ; Royal North Shore Hospital, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Sydney, Australia.; School of Medicine, University of Sydney, Sydney, Australia.; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia., Tischler AS; Department of Pathology and Laboratory Medicine, Tufts University School of Medicine, Boston, MA, USA., de Krijger RR; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Papathomas T; Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK., Aust D; Institute of Pathology, Tumor and Normal Tissue Bank of the UCC/NCT Dresden, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Eisenhofer G; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Department of Medicine III, University Hospital Dresden, Dresden, Germany., Richter S; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Publikováno v: The Journal of pathology [J Pathol] 2020 Aug; Vol. 251 (4), pp. 378-387. Date of Electronic Publication: 2020 Jul 01.

Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.

Autor: Calsina B; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Castro-Vega LJ; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France., Torres-Pérez R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Inglada-Pérez L; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Currás-Freixes M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Roldán-Romero JM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Mancikova V; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Letón R; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Remacha L; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Santos M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Burnichon N; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France.; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris, France., Lussey-Lepoutre C; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Sorbonne Université, Pitié-Salpêtrière Hospital, Department of nuclear medicine, Paris, France., Rapizzi E; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Graña O; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Álvarez-Escolá C; Servicio de Endocrinología y Nutrición, Hospital Universitario La Paz, Madrid, Spain., de Cubas AA; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Lanillos J; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Cordero-Barreal A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Martínez-Montes ÁM; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Bellucci A; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Radiologie, Paris, France., Amar L; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France., Fernandes-Rosa FL; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France., Calatayud M; Department of Endocrinology and Nutrition Service, Hospital Universitario 12 de Octubre, Madrid, Spain., Aller J; Department of Endocrinology, Puerta de Hierro University Hospital, Madrid, Spain., Lamas C; Department of Endocrinology, Albacete University Hospital Complex, Albacete, Spain., Sastre-Marcos J; Department of Endocrinology, Virgen de la Salud Hospital-Toledo Hospital Complex, Toledo, Spain., Canu L; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Korpershoek E; Department of Pathology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Timmers HJ; Department of Internal Medicine, Radboud University Medical Centre, 6525 HP Nijmegen, The Netherlands., Lenders JW; Department of Internal Medicine, Radboud University Medical Centre, 6525 HP Nijmegen, The Netherlands.; Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Beuschlein F; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.; Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland., Fassnacht-Capeller M; Department of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital Würzburg, University of Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University of Würzburg, Germany., Eisenhofer G; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Mannelli M; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy., Al-Shahrour F; Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Favier J; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France., Rodríguez-Antona C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Cascón A; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain., Montero-Conde C; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Gimenez-Roqueplo AP; INSERM, UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.; Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté de Médecine, Paris, France.; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris, France., Robledo M; Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.

Publikováno v: Theranostics [Theranostics] 2019 Jul 09; Vol. 9 (17), pp. 4946-4958. Date of Electronic Publication: 2019 Jul 09 (Print Publication: 2019).